<DOC>
	<DOCNO>NCT00016341</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Estrogen stimulate growth tumor cell . Hormone therapy use tamoxifen megestrol may fight endometrial cancer block absorption estrogen . It yet know whether chemotherapy effective hormone therapy treat endometrial cancer . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy hormone therapy treat patient recurrent , stage III , stage IV endometrial cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Compared With Hormone Therapy Treating Patients With Recurrent , Stage III , Stage IV Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare progression-free survival response patient stage III IV recurrent endometrial cancer treat doxorubicin , cisplatin , paclitaxel , filgrastim ( G-CSF ) v tamoxifen megestrol . - Compare survival patient treat regimen . - Determine progesterone receptor status provide information whether patient likely benefit chemotherapy . - Compare toxicity profile treatment regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , cross-over , multicenter study . Patients stratify accord progesterone receptor status ( negative v positive ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive chemotherapy comprise doxorubicin IV 15-30 minute follow cisplatin IV 1 hour day 1 ; paclitaxel IV 3 hour day 2 ; filgrastim ( G-CSF ) subcutaneously begin day 3 continue 10 day . Chemotherapy repeat every 21 day 7 course absence disease progression unacceptable toxicity . - At time disease progression , patient cross-over hormonal therapy arm II . - Arm II : Patients receive hormonal therapy comprise oral megestrol twice daily week 1-3 follow oral tamoxifen twice daily week 4-6 . Hormonal therapy repeat every 6 week absence disease progression unacceptable toxicity . At time disease progression , patient previously enrol arm I , patient cross-over receive chemotherapy arm I . Quality life assess baseline , 6 week , time progression , 6 week cross-over therapy . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 630 patient accrue study within 42 month .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary stage III IV recurrent endometrial cancer Poor curative potential radiotherapy surgery ( alone combination ) Measurable disease At least one lesion accurately measure least one dimension At least 20 mm conventional technique , include palpation , xray , CT scan , MRI OR At least 10 mm spiral CT scan Disease previously irradiate field sole site measurable disease allow clear progression completion radiotherapy Estrogen receptor ( ER ) /progesterone receptor ( PR ) status primary tumor require ER/PR status measurable tumor optional PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm^3 Granulocyte count least 1,500/mm^3 Hepatic : Bilirubin normal SGPT great 3 time upper limit normal Renal : Creatinine great 1.6 mg/dL Cardiovascular : LVEF least 50 % No thirddegree complete heart block , unless pacemaker place Other conduction abnormality cardiac dysfunction allow investigator 's discretion No history deep venous thrombosis No uncontrolled angina Pulmonary : No history pulmonary embolus Other : No malignancy within past 5 year except nonmelanoma skin cancer No concurrent medical illness would preclude study No serious uncontrolled infection No serious peripheral neuropathy No circumstance would preclude study compliance No sensitivity E. coliderived drug preparation PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy allow Chemotherapy : No prior cytotoxic chemotherapy , include chemotherapy radiosensitization Endocrine therapy : No prior hormonal therapy endometrial cancer Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy involve whole pelvis 50 % spine Surgery : See Disease Characteristics Other : Concurrent cardiac conductionaltering medication digitalis , beta blocker , calcium channel blocker allow investigator 's discretion</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
</DOC>